361 results about "Organ function" patented technology

Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

Stem cells, including mammalian, and particularly primate primordial stem cells (pPSCs) such as human embryonic stem cells (hESCs), hold great promise for restoring cell, tissue, and organ function. However, cultivation of stem cells, particularly undifferentiated hESCs, in serum-free, feeder-free, and conditioned-medium-free conditions remains crucial for large-scale, uniform production of pluripotent cells for cell-based therapies, as well as for controlling conditions for efficiently directing their lineage-specific differentiation. This instant invention is based on the discovery of the formulation of minimal essential components necessary for maintaining the long-term growth of pPSCs, particularly undifferentiated hESCs. Basic fibroblast growth factor (bFGF), insulin, ascorbic acid, and laminin were identified to be both sufficient and necessary for maintaining hESCs in a healthy self-renewing undifferentiated state capable of both prolonged propagation and then directed differentiation. Having discerned these minimal molecular requirements, conditions that would permit the substitution of poorly-characterized and unspecified biological additives and substrates were derived and optimized with entirely defined constituents, providing a “biologics”-free (i.e., animal-, feeder-, serum-, and conditioned-medium-free) system for the efficient long-term cultivation of pPSCs, particularly pluripotent hESCs. Such culture systems allow the derivation and large-scale production of stem cells such as pPSCs, particularly pluripotent hESCs, in optimal yet well-defined biologics-free culture conditions from which they can be efficiently directed towards a lineage-specific differentiated fate in vitro, and thus are important, for instance, in connection with clinical applications based on stem cell therapy and in drug discovery processes.

A family of minimally-invasive surgical (MIS) cardiac interventional tools with tactile feedback based upon cardiac mechanical data and physiologic parameters derived from sensors positioned upon the tools are configurable for optimal placement of an end-effector to provide acute cardiac resuscitation and / or remote cardiovascular intervention for a subject. A haptic interface (e.g., a haptic handle, haptic glove or a simulated haptic heart) provides a clinician with real, not virtual, interaction with the cardiovascular anatomy (including intrathoracic organs) of the subject to optimize end-effector placement. The MIS tools optionally include webbed blade portions for exploration of extracardiac or intrathoracic spaces. The blade portions are initially collapsed but expand into an array of finger-like projections that function as sensors, dilatation and / or dissection tools, pharmacological delivery tools, and / or electrodes for sensing, pacing and defibrillation, and / or as a manual, semi-automatic or fully automatic mechanical support system for cardiac resuscitation and / or for restoring intrathoracic organ function(s).

A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and / or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.

The invention belongs to the technology field of formula foodstuff with homology of medicine and food, and concretely relates to edible special meal for patients with tumor. Partial lump is formed by abnormal hyperplasia of cells of partial tissue under the effects of various tumorigenesis factors of body. The malignant tumor can destroy structure and function of tissue and organ, thereby inducing necrotic hemorrhage concurrent infection, and the patient finally may die due to exhaustion of organ function. The invention combines food material with homology of medicine and food as well as new resource foodstuff perfectly, and combines diet and health preserving organically, thereby using a plurality of probiotics creatively based on inherits of traditional Chinese medicine healing methods for conditioning and preventing and inhibiting tumor, and adjusting microecology balance in intestine and enhancing taste movement function; according to the characteristics of tumor, a plurality of natural and original medicine and food materials with homology are added, so the invention has unique advantages integrated with dietotherapy, prevention and conditioning three efficacies.

The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and / or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.

The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney. In certain embodiments, the methods involve administering to a human having thickened arterioles in brain, kidney or alveoli a peptide that ranges in length up to 30 amino acids, and that comprises a class A amphipathic helix, and bears at least one protecting group.

This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing excess insulin manufacture. This process improves cellular respiration and expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell / organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs. By decreased drain of cellular energy, genomic function improves.

The present invention is TAH system for auto-regulating blood flow and maintaining the asymmetric pressure balance in the mammalian cardiovascular system by decreasing the resistance in blood flow and minimizing the pressure gradients to exploit the in-flow pressure sensitivities of continuous flow pumps. The system further includes laminar flow generating manifolds connected to the atrium at one end and attached to pumps linked to the great vessels at the other, such that the in-let flow sensitivities of the pumps are maximized to auto-regulate blood flow, providing adequate pulmonary and systemic arterial flow to support normal metabolism and end-organ function and maintain the appropriate asymmetric physiologic pressure balance between the systemic and pulmonary systems of the mammalian cardiovascular system.

A nanoporous silicon support comprising a plurality of macropores is provided to function as a bioreactor for the maintenance of cells in culture in a differentiated state. Each cell or group of cells is grown in an individual macropore and is provided with nutrients by means such as perfusion of the nanoporous silicon support with fluid. The macropores may be between 0.2 and 200 microns and be coated with a substance that promotes cell adhesion. The support containing cells may be used to used to test compounds for biological activity, metabolism, toxicity, mutagenicity, carcinogenicity or to characterize novel or unknown comounds. The supports are sufficiently robust that they may be assembled into larger reactors to simulate organ function or be used for the production of biomolecules.

The invention discloses a making method for loofah sponge cloth shoes. Making of the loofah sponge cloth shoes can be completed through the steps of early-stage preparation, cloth board making, sole making, sole smoking and upper sewing. The making method has the advantages that the loofah sponge cloth shoes can improve circulation capacity of blood of the feet, dispel pain in the feet, remove fatigue, kill bacteria on the feet, remove dermatophytosis, reduce breeding of bacteria, prevent foot diseases, prevent foot odor, simulate foot acupoints, achieve a massage effect, dredge the channel, improve the organ functions of the body and achieve a healthcare effect; besides, no chemical substance is adopted in the making process, and therefore the loofah sponge cloth shoes are ecological and environmentally friendly, will not harm the body, can protect the health of people and is good in ecology and healthcare effect and easy to popularize.

Gene expression is measured in a sample of peripheral blood mononuclear cells (PBMCs) obtained from a subject and used to predict organ function recovery. A Function Recovery Potential (FRP) score is assigned to a sample that reflects the measured expression level of the genes identified herein in a direction associated with recovery from organ failure. Treatment of the subject with optimal medical management (OMM) and / or palliative care (PC) is advised when the FRP score is lower than the reference value, and referring the subject for treatment with therapies including—but not limited to—mechanical circulatory support (MCS) surgery, heart transplant (HTx) surgery, or other intervention for advanced heart failure is advised when the FRP score is greater than the reference value. A method for developing an FRP scoring algorithm that predicts a subject's ability to recover from medical intervention for organ failure is also described.